Inorganic phosphate (Pi)

Inorganic phosphate ions in the intestinal lumen are a critical therapeutic target for managing mineral imbalances in patients with impaired renal function, particularly those with Chronic Kidney Disease (CKD) (StatPearls, 2023). In healthy individuals, dietary phosphate is absorbed through the intestinal wall via both active transport (mediated by sodium-phosphate cotransporters like NaPi-2b) and passive paracellular diffusion (PubMed, 2021). However, when the kidneys lose the ability to excrete excess phosphorus, hyperphosphatemia develops, triggering a cascade of pathological events including the elevation of parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) (NIH, 2022). This biochemical disruption leads to secondary hyperparathyroidism, renal bone disease, and systemic vascular calcification, which significantly increases cardiovascular mortality. Pharmacological intervention focuses on the use of phosphate binders, which are orally administered agents that chemically interact with phosphate ions within the gut lumen (Journal of Clinical Medicine, 2021). By forming insoluble precipitates or complexes, these drugs effectively trap dietary phosphate and facilitate its excretion in the feces, thereby lowering systemic phosphorus burden and mitigating long-term complications.

Other names

Phosphate ions in the intestinal lumenIntestinal phosphatePO4(3-)Dietary phosphateOrthophosphate

Phosphate binders act by binding to dietary inorganic phosphate in the gastrointestinal tract to form insoluble complexes that are subsequently excreted in the feces, thereby preventing systemic absorption into the bloodstream (NIH, 2022).